Recombinant human IL-15 (rhIL-15) in combination with anti-PD-L1 (Avelumab) in SIV infected rhesus macaques leads to the expansion of a subset of CXCR3+PD1−/low CD8 T cells

Maha Moussa, Jie Cheng, Ping Chen, Hui Chen, Tong Li, Jing Qin, Jeffrey D. Lifson, Michael C. Sneller, Ludmila Krymskaya, Steven Godin, Clifford Lane, Marta CatálfamoThe Journal of Immunology 2019 · DOI

Abstract

Abstract The PD1/PD-L1 pathway contributes to the pathogenesis of HIV/SIV infection. Expression of PD1 by HIV/SIV-specific CD8 T cells can limit antiviral responses and expression of checkpoint receptors including PD1 by HIV infected cells can contribute to maintenance of viral reservoirs. In addition, reports have shown that IL-15 induces the expansion of effector memory CD8 T and NK cells. In this study, we hypothesized that expansion of memory CD8 T cells in the context of PD1/PD-L1 blockade may lead to enhanced anti-SIV responses. We design a study in which we evaluated the effect of rhIL-15 administered in cycles of ten days by continuous infusion in combination with weekly administration of anti-PD-L1 (Avelumab) over 24 weeks. After seven doses of anti-PD-L1 and completion of two cycles of rhIL15, cART therapy was interrupted and anti-PD-L1 administration continued to complete 24 weeks treatment. We found that administration of rhIL-15 in combination with anti-PD-L1 treatment was well tolerated. rhIL-15 infusions were associated with transient increases in proliferation of NK cells and effector memory CD8 T cells. rhIL-15/anti-PD-L1 treatment led to a sustained expression of CXCR3+ with low to undetectable expression of PD1on CD8 T cells, suggesting potential of increased tissue trafficking. Multidimensional single cell analysis showed that CXCR3+PD1−/low CD8 T cells secrete cytokine in response to viral antigens. Despite these clear biological effects, no impact was observed on rebound plasma viremia after cART discontinuation and during anti-PD-L1 administration. Futures studies should characterize the CXCR3+PD1−/low CD8 T cell subset expanded by this treatment to understand the potential impact of this subset in viral control.
BibTeX
@article{moussa2019recombinant,
  author = {Maha Moussa and Jie Cheng and Ping Chen and Hui Chen and Tong Li and Jing Qin and Jeffrey D. Lifson and Michael C. Sneller and Ludmila Krymskaya and Steven Godin and Clifford Lane and Marta Catálfamo},
  title = {{Recombinant human IL-15 (rhIL-15) in combination with anti-PD-L1 (Avelumab) in SIV infected rhesus macaques leads to the expansion of a subset of CXCR3+PD1−/low CD8 T cells}},
  journal = {The Journal of Immunology},
  year = {2019},
  doi = {10.4049/jimmunol.202.supp.72.13},
}

Loading related content...

Figure